News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis Therapeutics’ 2022 annual report published

March 28, 2023

Stockholm, Sweden, March 28, 2023 – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) Annual Report for 2022 is available (in Swedish) at the Company’s website, www.egetis.com. An English translation of the Annual Report will be published shortly.
 
For further information, please contact:

Nicklas Westerholm, CEO
[email protected]
+46 (0) 733 542 062

Yilmaz Mahshid, CFO
[email protected]
+46 (0) 722 316 800

Karl Hård, Head of Investor Relations and Communications
[email protected]
+46 (0) 733 011 944

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]